Spruce Biosciences (SPRB) Net Cash Flow (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Net Cash Flow of $5.2 million for Q1 2026, up 139.38% year-over-year from $2.2 million in Q1 2025, and down 89.87% quarter-over-quarter from $51.1 million in Q4 2025.
Spruce Biosciences (SPRB) Net Cash Flow (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Net Cash Flow for 8 consecutive years, with $5.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 139.38% year-over-year to $5.2 million; the TTM figure through Mar 2026 stood at $95.1 million (up 271.22% YoY), while the FY2025 annual figure was $76.8 million, up 233.33% from the prior year.
- Net Cash Flow declined to $5.2 million in Q1 2026 per SPRB's latest filing, from $51.1 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $51.1 million in Q4 2025 and bottomed at -$25.6 million in Q3 2022.
- Historically, Net Cash Flow has averaged $4.6 million across 5 years, with a median of -$2.5 million in 2023.
- Annual changes were most pronounced in 2024 — Net Cash Flow sank 829.95% — and 2025, when it jumped 599.1%.
- Spruce Biosciences' Net Cash Flow stood at $2.9 million in 2022, then tumbled by 185.84% to -$2.5 million in 2023, then sank by 765.58% to -$21.3 million in 2024, then soared by 339.86% to $51.1 million in 2025, then plunged by 89.87% to $5.2 million in 2026.
- Business Quant data shows SPRB's Net Cash Flow at $5.2 million in Q1 2026, $51.1 million in Q4 2025, and $48.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.19 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.58 Bn | 77.59 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.34 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.52 Bn | 51.38 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.67 Bn | 27.36 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.27 Bn | 26.11 Bn | 358.27 Mn | -37.14 Mn |
| 8 | BioNTech SE | 27.14 Bn | 8.75 Bn | 668.28 Mn | -2.83 Bn |
| 9 | Royalty Pharma | 27.12 Bn | 26.28 Bn | - | 225.59 Mn |
| 10 | Spruce Biosciences | 127.58 Mn | 127.58 Mn | - | 103.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 103.97 Mn |
| Jun 30, 2026 | 103.97 Mn |
| Mar 31, 2026 | 5.17 Mn |
| Mar 31, 2026 | 5.17 Mn |
| Dec 31, 2025 | 51.09 Mn |
| Dec 31, 2025 | 51.09 Mn |
| Sep 30, 2025 | 48.05 Mn |
| Sep 30, 2025 | 48.05 Mn |
| Jun 30, 2025 | -9.23 Mn |
| Jun 30, 2025 | -9.23 Mn |
| Mar 31, 2025 | -13.14 Mn |
| Mar 31, 2025 | -13.14 Mn |
| Dec 31, 2024 | -21.30 Mn |
| Dec 31, 2024 | -21.30 Mn |
| Sep 30, 2024 | -9.63 Mn |
| Sep 30, 2024 | -9.63 Mn |
| Jun 30, 2024 | -11.47 Mn |
| Jun 30, 2024 | -11.47 Mn |
| Mar 31, 2024 | -15.19 Mn |
| Mar 31, 2024 | -15.19 Mn |